Heparin-induced thrombocytopenia classification: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Protected "Heparin-induced thrombocytopenia classification": Robot: Protecting all pages from category Drugs ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(No difference)

Revision as of 16:58, 20 December 2011

Heparin-induced thrombocytopenia

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Heparin-induced thrombocytopenia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Heparin-induced thrombocytopenia classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Heparin-induced thrombocytopenia classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Heparin-induced thrombocytopenia classification

CDC on Heparin-induced thrombocytopenia classification

Heparin-induced thrombocytopenia classification in the news

Blogs on Heparin-induced thrombocytopenia classification

Directions to Hospitals Treating Heparin-induced thrombocytopenia

Risk calculators and risk factors for Heparin-induced thrombocytopenia classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3]

Overview

Heparin-induced thrombocytopenia is diagnosed when the platelet count falls by > 50% typically after 5-10 days of heparin therapy. There are two forms of HIT. Type II HIT is the main adverse effect of heparin use.

Classification

There are two forms of HIT. Type II HIT is the main adverse effect of heparin use.

Type I

  • In this form patients characteristically have a transient decrease in platelet count (rarely <100,000) without any further symptoms.
  • This thrombocytopenia recovers even if heparin is continued to be administered.
  • It occurs in 10-20% of all patients on heparin.
  • It is not due to an immune reaction and antibodies are not found upon investigation.
  • HIT-1 is due to heparin-induced platelet clumping; it is innocuous.

Type II

  • This form is due to an autoimmune reaction with antibodies formed against platelet factor 4 (PF4), neutrophil-activating peptide 2 (NAP-2) and interleukin 8 (IL8) which form complexes with heparin.
  • The most common form is to the heparin-PF4 complex.
  • Heparin binding to platelet factor 4 causes a conformational change in the protein, rendering it antigenic.
  • Antibodies bind to these complexes, activate the surrounding platelets and generate thrombin.
  • The antibodies found are most commonly are of the IgG class with or without IgM and IgA class antibodies.
  • IgM and IgA are rarely found without IgG antibodies.
  • Type II HIT develops in about 3% of all patients on UFH and in 0.1% of patients on LMWH, and causes thrombosis in 30% to 40% of these patients.
  • The other patients are able to compensate for the activation of hemostasis that leads to thrombosis.
  • Clot formation is mainly arterial
  • Most thrombotic events are in the lower limbs, skin lesions and necrosis may also occur at the site of the heparin infusion.
  • Rapid-onset HIT can result in life-threatening acute systemic reactions (eg rigors, fever, hypertension, tachycardia) and cardiopulmonary collapse.
  • Single or trivial doses of heparin, such as catheter flushes, can cause HIT.
  • In HIT2 the onset of thrombocytopenia is independent of the type of heparin, dose and route of administration.
  • HIT antibodies can persist for 4-6 weeks but disappear after 3 months.
  • The presence of HIT antibodies, even at higher titer, doesn't predict an increase in complications.
  • An increase in the titers of the antibodies do, however, give an increase in the in-vitro activaton of the coagulation system.
  • The ELISA test, though not ideal, is the best predictive diagnostic test of HIT2. It has been suggested that HIT2 only occurs with high antibody titers and after persistent exposure to heparin; also it suggests that antigens different from the H-PF4 complex can be involved. There may be a HIT antibody active in a non-heparin dependent manner. Data exists suggesting that there are "superactive" HIT antibodies capable of activating platelets without heparin.

Reference